Top 10 Companies in the Global Molecular Diagnostics Market

The global molecular diagnostics market was valued at USD 20.57 billion in 2024. The market is expected to grow at a CAGR of 8.20% during the forecast period of 2025-2034, with the value likely to reach USD 45.24 billion by 2034. As per the analysis by Expert Market Research, the market is anticipated to expand significantly, driven by the rising innovation in molecular diagnostic technologies and their widespread application across the globe.

The market is poised to be driven by continuous advancements in molecular diagnostic technologies (such as next-generation sequencing (NGS), polymerase chain reaction, and microarrays). The market is also witnessing escalating demand for personalised medicines along with favourable regulatory policies to boost the approval of upcoming molecular diagnostic tests.

The market is influenced by several trends such as increasing efforts toward research and development to improve the existing molecular diagnostic technologies such as nucleic acid detection in various diagnostic settings in the early phases of disease. Further, the market is experiencing significant technological advancements and strategic collaborations between academic institutions, diagnostic companies, and healthcare providers resulting in expanded market reach.

In January 2023, Alveo signed a Memorandum of Understanding (MOU) with the Barbados Investment and Development Corporation (Export Barbados (BIDC)) to co-develop its novel molecular sensing platform, while contributing to the growth of the life sciences industry in the Caribbean nation. Additionally, as the demand for rapid and on-site molecular testing is increasing, companies are focusing on bringing better point-of-care technologies into the market. For instance, MolBio, a cutting-edge company specialising in molecular diagnostics set to bring numerous innovative point-of-care technologies in the domains of haematology, cancer, anti-microbial resistance (AMR), next-generation sequencing (NGS), and syndromic testing, among others.

Leaders in the Molecular Diagnostics Market Worldwide

1.    BioMérieux SA

BioMérieux SA is a French multinational biotechnology company that provides diagnostic solutions to determine the source of infection in patients resulting in improved health and patient outcomes.Their products are used to diagnose infectious diseases, cancer screening, monitoring, and cardiovascular emergencies.

2.    BD (Becton, Dickinson and Company)

BD (Becton, Dickinson and Company) is an American multinational medical technology company that has a range of molecular diagnostic solutions in its portfolio. The company has a prominent product called BD MAX™ System, which is its major contribution to the market.

3.    Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. is an American company that develops and manufactures technological products for research studies associated with life science and clinical diagnostics markets. Bio-Rad has given numerous testing products to the molecular diagnostics market and has significantly revolutionised the testing approaches for respiratory, virology, microbiology, and sexually transmitted infections, along with tick-borne diseases.

4.    Abbott

Abbott Laboratories is an American multinational medical device and healthcare company. Abbott is a major player in the market with various products to diagnose infectious diseases in patients. Urovysion Bladder Cancer Kit is one of Abbott’s most prominent products in the molecular diagnostics domain, playing a crucial role in the detection and monitoring of bladder cancer.

5.    Agilent Technologies, Inc.

Agilent Technologies, Inc. is a global company that provides instruments, software, services, and consumables for laboratories. The company collaborates with other market players strategically to support the advancement of portfolios associated with molecular testing. For instance, Agilent collaborated with Incyte to aid the development and commercialisation of Incyte’s expanding portfolio in hematology and oncology therapeutics.

6.    Hologic Inc.

Hologic, Inc. is a United States based medical technology company that prioritises women's health and develops and sells medical devices for diagnostics, surgery, and medical imaging in women. Hologic has provided the market with some of the most innovative technologies/solutions for detecting human diseases such as assays for sexually transmitted infections, respiratory diseases, and cervical cancer.

7.    Danaher Corporation

Danaher Corporation is a global conglomerate that manufactures a wide range of healthcare solutions. It has numerous diagnostic tools that are instrumental in the domain of molecular diagnostics. With prominent offerings like GeneXpert system, Danaher’s cutting-edge molecular diagnostic solution is instrumental in the detection and management of tuberculosis in patients.

8.    DiaSorin

DiaSorin is an Italian multinational biotechnology company that manufactures and sells in vitro diagnostic reagent kits, used in immunodiagnostics as well as molecular diagnostics. The company collectively went active in the life science business in July 2021. DiaSorin primarily brings diagnostic assays to the market along with a strong focus on the development of research and laboratory kits useful in the molecular diagnostics domain.

9.    Illumina, Inc.

Illumina, Inc. is an American biotechnology company. It is dedicated to the development, manufacturing, and marketing of cutting-edge integrated systems for analysing genetic variation and biological function. It has a wide range of assays and kits that support the progress of NGS-based molecular diagnostic tests for cystic fibrosis, colorectal cancer, and numerous other applications.

10.    Johnson & Johnson Services, Inc.

Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation. The company has been involved in various collaborations with a focus on providing increased access to molecular diagnostic tools for tuberculosis case detection and Multidrug-resistant (MDT-TB) diagnosis.